Physician
Oncology
Dr. Alain C. Mita, MD
|
|
Give Review
Alain Mita practices Oncology. Dr. Alain C. Mita is also a published physician. He has 69 publication published. The most recent publication is: Schedule-dependent paclitaxel tolerance/activity: data from a 7 day infusion phase I study with pharmacokinetics in paclitaxel refractory ovarian cancer. Alain Mita is registered with Medicare and accepts Medicare payments.
Publications
- Targeting survivin inhibits renal cell Carcinoma progression and enhances the activity of temsirolimus.
- A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in Medulloblastoma.
- Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid Tumors.
- Pharmacokinetic study of aldoxorubicin in patients with solid Tumors.
- Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid Tumors.
- Phase I study of cabazitaxel plus cisplatin in patients with advanced solid Tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketocona...
- Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib...
- Combined autophagy and HDAC inhibition: A phase I safety, tolerability, pharmacokinetic, and pharmacodynamic Analysis of hydroxychloroquine in combination with the HDA...
- A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors.
- Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer.
- A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid Tumors.
- Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignanc...
- Vascular-disrupting agents in oncology.
- Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid Tumors.
- Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic Tumors.
- Metabolism of patupilone in patients with advanced solid tumor Malignancies.
- Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced...
- The Hedgehog Knows Many Tricks.
- Heat Shock Proteins: A Potential AntiCancer Target.
- Clinical activity of mammalian target of rapamycin inhibitors in solid Tumors.
- Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin.
- Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid Tumors or lymphomas.
- Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid Tumors.
- Vorinostat enhances the activity of temsirolimus in renal cell Carcinoma through suppression of survivin levels.
- A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid Malignancies.
- Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid Tumors.
- Survivin: key regulator of mitosis and apoptosis and novel target for Cancer therapeutics.
- Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients...
- Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery System for paclitaxel.
- Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 Analogue, administered weekly for 3 weeks every 28 days in pati...
- Design, conDuct, and interpretation of organ impairment studies in oncology patients.
- Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced Cancer patients with normal and impaired renal function.
- Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced Cancer.
- Development of rationally designed, target-based agents for the treatment of advanced colorectal Cancer.
- Reovirus-based therapy for Cancer.
- Characterisation of the cutaneous pathology in non-small cell lung Cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
- The absence of functional glucosylceramide synthase does not sensitize melanoma cells for antiCancer drugs.
- Mammalian target of rapamycin: a new molecular target for breast Cancer.
- The molecular target of rapamycin (mTOR) as a therapeutic target against Cancer.
- Targeting the mTOR pathway using deforolimus in Cancer therapy.
- The emerging safety profile of mTOR inhibitors, a novel class of antiCancer agents.
- Targeted therapy for advanced non-small cell lung Cancers: historical perspective, current practices, and future development.
- Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid Malignancies.
- Are we ready to move away from nature?: the rapamycin story.
- Vascular Disrupting Agents (VDA) in Oncology: Advancing Towards New Therapeutic Paradigms in the Clinic.
- The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas.
- Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced Malignancies.
- Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced Malignancies: a phase I clinical trial.
- Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid Tumors.
- Erlotinib ''dosing-to-rash'': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung Cancer.
- Schedule-dependent paclitaxel tolerance/activity: data from a 7 day infusion phase I study with pharmacokinetics in paclitaxel refractory ovarian Cancer.
- 6-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory Malignancies.
- Antiproinflammatory effects of iodixanol (OptiPrep)-based density gradient purification on human islet preparations.
- Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats.
- beta-Cell specific cytoprotection by prolactin on human islets.
- Living-related Liver transplantation for patients with fulminant and subfulminant hepatic failure.
- Effect of human islet rescue gradient purification on islet yield and fractional Beta Cell viability.
- Toward improving human islet isolation from younger donors: rescue purification is efficient for trapped islets.
- Purification method using iodixanol (OptiPrep)-based density gradient significantly reduces cytokine chemokine proDuction from human islet preparations, leading to pro...
- Effect of pituitary adenylate cyclase-activating polypeptide in islet transplantation.
- A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced Cancer.
- Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.
- Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid Tumors.
- A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
- Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.
- Deforolimus (AP23573) a novel mTOR inhibitor in clinical development.
- Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid Malignancies.
- Targeting sarcomas: novel biological agents and future perspectives.
Schools
Universitatea De Medicina Si Farmacie Carol Davila Facultatea De Medicina
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Oncology
Accepted Insurances
Education
-
University of Texas Health Science Center -
Carol Davila University of Medicine and Pharmacy
Hospital
-
Santa Monica-UCLA Medical Center and Orthopaedic Hospital -
Cedars-Sinai Medical Center
Drug Facts
| NPI NUMBER | 1285602565 | |
| NPPES Provider LastName | MITA | |
| NPPES Provider FirstName | ALAIN | |
| NPPES Provider ZIPCode | 782293901 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 78.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1285602565 |
| Last Name Of The Provider | MITA |
| First Name Of The Provider | ALAIN |
| View All |
Similar Doctors
|
|
Dr. Sridhar Beeram, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Irene Kazhdan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sukeshi R. Patel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Virginia G. Kaklamani, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Lisa M. Fichtel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John Sarantopoulos, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jayasree N. Rao, MD
This Doctor is OpenDoctor Recommended.
|